sponsored byAAAS Golden Fund




Forgot Password?

Press Releases

Breaking News

Science Business

Grants, Awards, Books



Science Agencies
on EurekAlert!

US Department of Energy

US National Institutes of Health

US National Science Foundation


Submit a Calendar Item


Links & Resources


RSS Feeds

Accessibility Option On


Portal Home


Background Articles

Research Papers


Links & Resources

Disease in the Developing World

News Releases

Key: Meeting M      Journal J      Funder F

Showing releases 426-450 out of 1408.

<< < 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 > >>

Public Release: 6-Apr-2017
Ebola: New trial launched in west Africa to evaluate three vaccination strategies
The French National Institute of Health and Medical Research (Inserm), the US National Institutes of Health (NIH) and the London School of Hygiene & Tropical Medicine (LSHTM), in collaboration with health authorities in Guinea and Liberia, are launching a large clinical trial of candidate Ebola vaccines under the aegis of the PREVAC international consortium (Partnership for Research on Ebola VACcination).
The French National Institute of Health, Medical Research, London School of Hygiene & Tropical Medicine, NIH/National Institute of Allergy and Infectious Diseases

Contact: NIAID Office of Communications
NIH/National Institute of Allergy and Infectious Diseases

Public Release: 6-Apr-2017
Molecular Cell
Rutgers researchers determine structure of tuberculosis drug target
Rutgers University scientists have determined the three-dimensional structure of the target of the first-line anti-tuberculosis drug rifampin. They have also discovered a new class of potential anti-tuberculosis drugs that kill rifampin-resistant and multi-drug-resistant tuberculosis bacteria. Tuberculosis (TB) bacteria infect a third of the world's population and the disease kills 1.8 million people annually.
NIH/National Institute of General Medical Sciences, NIH/National Institute of Allergy and Infectious Diseases, Global Alliance for TB Drug Development

Contact: Todd B. Bates
Rutgers University

Public Release: 5-Apr-2017
Science Translational Medicine
Researchers develop Marburg virus treatment effective five days after infection
An antibody treatment successfully protected nonhuman primates against the deadly Marburg and Ravn viruses even when given five days after becoming infected, according to the latest findings of a collaborative team from The University of Texas Medical Branch at Galveston, Mapp Biopharmaceutical Inc., and Vanderbilt University.

Contact: Donna Ramirez
University of Texas Medical Branch at Galveston

Public Release: 5-Apr-2017
Science Translational Medicine
Monoclonal antibody cures Marburg infection in monkeys
Scientists funded by the National Institutes of Health have found that an experimental treatment cured 100 percent of guinea pigs and rhesus monkeys in late stages of infection with lethal levels of Marburg and Ravn viruses, relatives of the Ebola virus. Although the Marburg and Ravn viruses are less familiar than Ebola virus, both can resemble Ebola in symptoms and outcomes in people, and both lack preventive and therapeutic countermeasures.
NIH/National Institute of Allergy and Infectious Diseases

Contact: Ken Pekoc
NIH/National Institute of Allergy and Infectious Diseases

Public Release: 5-Apr-2017
BMC Health Services Research
Curbing alcohol to fight HIV could save money in Kenya
Expanding a program in Kenya that fights the spread of HIV by curbing alcohol consumption could produce a net economic benefit, a new study projects.
National Institutes of Health

Contact: David Orenstein
Brown University

Public Release: 5-Apr-2017
American Chemical Society 253rd National Meeting & Exposition
Addictive nut's derivatives could help smokers break the nicotine habit
As many as 600 million people in Asia chew areca nuts with betel leaves, sometimes adding tobacco leaves. Many users are addicted to this harmful preparation, which can create a sense of euphoria. Yet researchers have now discovered that compounds derived from the nut could help cigarette smokers -- as well as betel quid chewers -- kick their habits. They present their work today at the 253rd National Meeting & Exposition of the American Chemical Society.

Contact: Katie Cottingham
American Chemical Society

Public Release: 4-Apr-2017
Pre-existing immunity to dengue and West Nile may cause increased risk in Zika-infected
As the Zika virus continues to spread rapidly across the globe, it might pose a particular risk to people previously infected with two related viruses, dengue and West Nile, researchers at the Icahn School of Medicine at Mount Sinai have found. Their study, published in the journal Science, may help explain the severe manifestations of Zika virus infection observed in specific populations, including those in South America.

Contact: Lucia Lee
The Mount Sinai Hospital / Mount Sinai School of Medicine

Public Release: 4-Apr-2017
KU Leuven to lead development of dual vaccine against yellow fever and rabies
Rabies and yellow fever claim ten thousands of lives each year. Vaccines already exist but various drawbacks that hinder their efficient distribution. One of them is the need to transport and store these vaccines at cool temperatures. The RABYD-VAX consortium, led by KU Leuven (University of Leuven, Belgium), has now started developing a cheap, temperature-stable, and easy-to-produce vaccine against both diseases at once.
European Union's Horizon 2020 Research and Innovation Programme

Contact: Johan Neyts
KU Leuven

Public Release: 4-Apr-2017
MERS-like coronavirus identified in Ugandan bat
A team of researchers in the United States and Uganda has identified a novel coronavirus in a bat from Uganda that is similar to the one causing Middle East Respiratory Syndrome (MERS) in people, giving further credence to the theory that such viruses originate in bats. The work was described this week in mBio®, an online open-access journal of the American Society for Microbiology.
United States Agency for International Development Emerging Pandemic Threats PREDICT project, NIH/National Institutes of Allergy and Infectious Disease, NIH/National Institute of Diabetes and Digestive and Kidney Diseases

Contact: Tim Paul
Columbia University's Mailman School of Public Health

Public Release: 31-Mar-2017
University of Miami to begin phase 2 Zika vaccine trial
The University of Miami Miller School of Medicine will soon begin one of the nation's first full-scale Zika vaccine clinical trials testing the National Institutes of Health's (NIH) experimental DNA-based vaccine. As Miami-Dade County has been ground zero for the Zika virus outbreak in the U.S., testing the vaccine in an endemic region is critical to help determine the vaccine's safety, effective dosage and whether it can effectively prevent disease caused by Zika infection.
NIH/National Institute of Allergy and Infectious

Contact: Kai Hill
University of Miami

Public Release: 31-Mar-2017
European Journal of Preventive Cardiology
Insomnia associated with increased risk of heart attack and stroke
Insomnia is associated with increased risk of heart attack and stroke, according to research published today in the European Journal of Preventive Cardiology.

Contact: ESC Press Office
European Society of Cardiology

Public Release: 30-Mar-2017
Annals of Neurology
The US burden of neurological disease is nearly $800 billion/year
The most common neurological diseases cost the United States $789 billion in 2014, and this figure is projected to grow as the elderly population doubles between 2011 and 2050, according to a new study published in the April issue of the Annals of Neurology.

Contact: Dawn Peters & Tracy Simon

Public Release: 29-Mar-2017
Global immunization impact constrained by outdated vaccine delivery systems, researchers say
Outdated vaccine supply and distribution systems are delaying and limiting the impact that vaccines have on safeguarding people's health. Among the challenges of ensuring a consistent supply of potent vaccines identified by researchers: one in every three countries in the world experiences at least one stockout of at least one vaccine for at least one month; and 19 to 38 percent of vaccines worldwide are accidentally exposed to freezing temperatures, potentially compromising the potency of those vaccines.

Contact: Preeti Singh

Public Release: 28-Mar-2017
PLOS Neglected Tropical Diseases
Wealth and knowledge drive bushmeat consumption during the West African Ebola crisis
Bushmeat, or wild animal meat, is an essential source of protein for many people in tropical regions. But handling and eating bushmeat carries the risk of contracting diseases, such as Ebola virus disease (EVD). During the latest and largest ever recorded Ebola crisis, household income and specific knowledge about the risks of eating bushmeat were linked to changes in its consumption, researchers report in PLOS Neglected Tropical Diseases. Although bushmeat consumption in Liberia generally decreased during the crisis, preferences for bushmeat remained constant.

Contact: PLOS Neglected Tropical Diseases

Public Release: 28-Mar-2017
Population and Environment
Study finds that elevating women's status lowers dependence on solid fuels
A new research paper finds that in countries where gender inequalities are most pronounced, women are much more likely to be exposed to solid fuel -- including burning from wood, crop wastes, charcoal, and dung -- and its negative consequences.

Contact: Lauren Stralo
Lehigh University

Public Release: 28-Mar-2017
'Flying syringes' could detect emerging infectious diseases
Blood-sucking flies can act as 'flying syringes' to detect emerging infectious diseases in wild animals before they spread to humans, according to research published in the journal eLife.
Agence Universitaire de la Francophonie (AUF), Service de Coopération et d'Action Culturelle de l'ambassade de France au Gabon, LMI ZOFAC IRD, CIRMF, ANR JCJC 07-2012-ORIGIN

Contact: Emily Packer

Public Release: 28-Mar-2017
Molecular Biology and Evolution
Herpes STDs: From chimps to humans to cold sore cousin mixing before worldwide spread
Evolutionarily, Herpes simplex virus 1 and 2 are considered cousins, and are thought to have evolved independently, Now, an entirely new picture is emerging. While scientists did not find evidence of chimpanzee herpes virus fragments in HSV-2 genomes, they show the history of HSV-2 was marked by recombination with HSV-1. In addition, they determined two main lineages of HSV-2, one globally distributed and another restricted to sub-Saharan Africa, which both started diversifying about 30,000 years ago.

Contact: Joseph Caspermeyer
Molecular Biology and Evolution (Oxford University Press)

Public Release: 27-Mar-2017
Nature Communications
Zika virus protein mapped to speed search for cure
A study published today reports that a team led by Indiana University scientists has mapped a key protein that causes the Zika virus to reproduce and spread.
NIH/National Institute of General Medical Sciences, Howard Hughes Medical Institute, US Department of Energy

Contact: Kevin Fryling
Indiana University

Public Release: 27-Mar-2017
Journal of General Internal Medicine
A little nudge may provide a big boost to flu vaccination rates
Currently, only 44 percent of adults in the United States receive an annual flu vaccination. But, a new study suggests that a simple behavioral economics technique may be able to help. In the study, researchers programmed electronic health records (EHR) to alert care providers when a patient was eligible, and prompt them to choose to 'accept' or 'decline' a flu vaccination order. Results showed a 37 percent relative increase in vaccinations from the prior year.

Contact: Katie Delach
University of Pennsylvania School of Medicine

Public Release: 27-Mar-2017
Nature Communications
Researchers crack structure of key protein in Zika virus
The genomic replication of the Zika virus (ZIKV) is made possible by its 'NS5' protein. UC Riverside scientists report that they have determined the crystal structure of the entire ZIKV NS5 protein and demonstrated that NS5 is functional when purified in vitro. Knowing the structure of ZIKV NS5 helps the researchers understand how ZIKV replicates itself. Further, the researchers identified the inhibitor-binding site of NS5, enabling scientists to design potential potent drugs to fight ZIKV.
March of Dimes Foundation, Sidney Kimmel Foundation for Cancer Research, National Institutes of Health

Contact: Iqbal Pittalwala
University of California - Riverside

Public Release: 27-Mar-2017
Proceedings of the National Academy of Sciences
A new test to rapidly identify worldwide TB infections
A group of scientists from Arizona, Texas and Washington, D.C., has teamed up to develop the first rapid blood test to diagnose and quantify the severity of active TB cases. Led by Tony Hu, a researcher at Arizona State University's Biodesign Institute, eight research groups, including the Houston Methodist Research Institute and scientists at the National Institutes of Health, are harnessing the new field of nanomedicine to improve worldwide TB control.

Contact: Joe Caspermeyer
Arizona State University

Public Release: 24-Mar-2017
Future Science OA
New lab-on-a-chip platform seeks to improve pathogen detection
Researchers from the Fraunhofer Institute have developed a new prototype lab-on-a-chip platform for the easy and versatile detection of molecular pathogens.

Contact: Leela Ripton
Future Science Group

Public Release: 23-Mar-2017
Scientists assemble Zika virus mosquito genome from scratch
A team of scientists has developed a new way to sequence genomes, which can assemble the genome of an organism, entirely from scratch, dramatically cheaper and faster.

Contact: Graciela Gutierrez
Baylor College of Medicine

Public Release: 23-Mar-2017
Journal of Interferon & Cytokine Research
New understanding of chronic lung inflammatory diseases unfolding
Researchers studying chronic inflammation that can lead to the development of lung diseases such as asthma, pulmonary fibrosis, and cancer, are focusing on the role cytokines play in regulating the behavior of fibroblast cells and the extracellular matrix.

Contact: Kathryn Ryan
Mary Ann Liebert, Inc./Genetic Engineering News

Public Release: 23-Mar-2017
European Heart Journal
Cardiac lead extractions safer in high volume centers
Cardiac lead extraction is safer in high volume centers, according to the largest study of contemporary practice in Europe published today in European Heart Journal. Extraction in a low volume center was associated with a doubled risk of death while in hospital.
Boston Scientific, Cook Medical, Medtronic, Spectranetics and Zoll

Contact: ESC Press Office
European Society of Cardiology

Showing releases 426-450 out of 1408.

<< < 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 > >>